Related Experiment Video

Updated: Jul 19, 2026

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

Transcription-based COX-2 inhibition: a therapeutic strategy

Kenneth K Wu1

  • 1Vascular Biology Research Center and Division of Hematology, Department of Medicine, The University of Texas Health Science Center at Houston, Texas 77030, USA. Kenneth.K.Wu@uth.tmc.edu

Thrombosis and Haemostasis
|September 28, 2006
PubMed

Insights

Selective cyclooxygenase-2 (COX-2) inhibitors cause cardiovascular issues. Targeting transcription factors like C/EBPbeta, via inhibiting p90 ribosomal S6 kinase (RSK), offers a novel anti-inflammatory strategy with potentially fewer side effects.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Selective cyclooxygenase-2 (COX-2) inhibitors effectively manage inflammation but pose cardiovascular risks, limiting their use.
  • C/EBPbeta is a key transactivator for COX-2 gene expression, induced by inflammatory signals.
  • Transcription-based inhibition is proposed as a strategy to avoid COX-2 inhibitor complications.

Purpose of the Study:

  • To investigate transcription-based inhibition of COX-2 as a therapeutic approach.
  • To identify molecular targets for novel anti-inflammatory and anti-neoplastic drugs.

Main Methods:

  • Investigated the role of C/EBPbeta in COX-2 transcriptional activation.
  • Examined the effect of sodium salicylate on C/EBPbeta binding to the COX-2 promoter.
  • Assessed the role of p90 ribosomal S6 kinase (RSK) in regulating C/EBPbeta activity.

Main Results:

  • Sodium salicylate inhibits C/EBPbeta binding to the COX-2 promoter at pharmacological concentrations.
  • This inhibition occurs via direct suppression of p90 ribosomal S6 kinase (RSK) activity.
  • RSK phosphorylates C/EBPbeta, enhancing its DNA-binding affinity.

Conclusions:

  • RSK1/2 is identified as a potential therapeutic target for developing novel anti-inflammatory drugs.
  • Targeting RSK offers a strategy to inhibit COX-2 expression transcriptionally, potentially circumventing cardiovascular side effects.
  • This approach holds promise for both anti-inflammatory and anti-neoplastic therapies.

More Related Videos

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers10:28

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Published on: September 20, 2018

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...